GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IDEXX Laboratories Inc (NAS:IDXX) » Definitions » EV-to-EBIT

IDEXX Laboratories (IDEXX Laboratories) EV-to-EBIT

: 36.54 (As of Today)
View and export this data going back to 1991. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, IDEXX Laboratories's Enterprise Value is $40,300 Mil. IDEXX Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $1,103 Mil. Therefore, IDEXX Laboratories's EV-to-EBIT for today is 36.54.

The historical rank and industry rank for IDEXX Laboratories's EV-to-EBIT or its related term are showing as below:

IDXX' s EV-to-EBIT Range Over the Past 10 Years
Min: 17.37   Med: 39.6   Max: 70.45
Current: 36.54

During the past 13 years, the highest EV-to-EBIT of IDEXX Laboratories was 70.45. The lowest was 17.37. And the median was 39.60.

IDXX's EV-to-EBIT is ranked worse than
78.9% of 109 companies
in the Medical Diagnostics & Research industry
Industry Median: 19.17 vs IDXX: 36.54

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. IDEXX Laboratories's Enterprise Value for the quarter that ended in Dec. 2023 was $46,700 Mil. IDEXX Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $1,103 Mil. IDEXX Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 2.36%.


IDEXX Laboratories EV-to-EBIT Historical Data

The historical data trend for IDEXX Laboratories's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDEXX Laboratories Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.11 62.34 60.66 39.09 42.35

IDEXX Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.09 45.83 40.73 34.36 42.35

Competitive Comparison

For the Diagnostics & Research subindustry, IDEXX Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IDEXX Laboratories EV-to-EBIT Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where IDEXX Laboratories's EV-to-EBIT falls into.



IDEXX Laboratories EV-to-EBIT Calculation

IDEXX Laboratories's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=40300.001/1102.757
=36.54

IDEXX Laboratories's current Enterprise Value is $40,300 Mil.
IDEXX Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,103 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IDEXX Laboratories  (NAS:IDXX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

IDEXX Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=1102.757/46700.3326
=2.36 %

IDEXX Laboratories's Enterprise Value for the quarter that ended in Dec. 2023 was $46,700 Mil.
IDEXX Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,103 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IDEXX Laboratories EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of IDEXX Laboratories's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


IDEXX Laboratories (IDEXX Laboratories) Business Description

Address
One IDEXX Drive, Westbrook, ME, USA, 04092
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 40% of its revenue from outside the United States.
Executives
James F Polewaczyk officer: Corporate Vice President IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Jonathan Jay Mazelsky director, officer: President and CEO ONE IDEXX DRIVE, WESTBROOK ME 04092
Martin Alexander Smith officer: Executive Vice President C/O IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Jonathan W Ayers director, officer: President & CEO IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Michael Lane officer: Executive Vice President C/O IDEXX LABORATORIES, INC., WESTBROOK ME 04092
Irene Chang Britt director CAMPBELL SOUP COMPANY, ONE CAMPBELL PLACE, CAMDEN NJ 08103
Bruce L. Claflin director 7035 RIDGE ROAD, HANOVER MD 21076
Samer Abdul Samad director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Stuart Essig director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Lawrence D Kingsley director C/O IDEX CORPORATION, 630 DUNDEE ROAD, NORTHBROOK IL 60062
Asha Collins director IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
M Anne Szostak director C/O TUPPERWARE BRANDS CORP, 14901 S ORANGE BLOSSOM TR, ORLANDO FL 32837
Sharon E. Underberg officer: EVP, GC & Corporate Secretary EASTMAN KODAK COMPANY, 343 STATE STREET, ROCHESTER NY 14650
Sophie V. Vandebroek director 6 OAK MEADOW ROAD, LINCOLN MA 01770
Daniel M Junius director C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451

IDEXX Laboratories (IDEXX Laboratories) Headlines